Workman Antony J, Kane Kathleen A, Russell Julie A, Norrie John, Rankin Andrew C
Section of Cardiology, Division of Cardiovascular and Medical Sciences, University of Glasgow, Royal Infirmary, 10 Alexandra Parade, G31 2ER, Glasgow, UK.
Cardiovasc Res. 2003 Jun 1;58(3):518-25. doi: 10.1016/s0008-6363(03)00263-3.
Chronic beta-adrenoceptor antagonist (beta-blocker) treatment reduces the incidence of reversion to AF in patients, possibly via an adaptive myocardial response. However, the underlying electrophysiological mechanisms are presently unclear. We aimed to investigate electrophysiological changes in human atrial cells associated with chronic treatment with beta-blockers and other cardiovascular-acting drugs.
Myocytes were isolated enzymatically from the right atrial appendage of 40 consenting patients who were in sinus rhythm. The cellular action potential duration (APD), effective refractory period (ERP), L-type Ca(2+) current (I(CaL)), transient (I(TO)) and sustained (I(KSUS)) outward K(+) currents, and input resistance (R(i)) were recorded using the whole cell patch clamp. Drug treatments and clinical characteristics were compared with electrophysiological measurements using simple and multiple regression analyses. P<0.05 was taken as statistically significant.
In atrial cells from patients treated chronically with beta-blockers, the APD(90) and ERP (75 beats/min stimulation) were significantly longer, at 213+/-11 and 233+/-11 ms, respectively (n=15 patients), than in cells from non-beta-blocked patients, at 176+/-12 and 184+/-12 ms (n=11). These cells also displayed a significantly reduced action potential phase 1 velocity (22+/-3 vs. 34+/-3 V/s). Chronic beta-blockade was also associated with a significant reduction in the heart rate (58+/-3 vs. 69+/-5 beats/min) and in the density of I(TO) (8.7+/-1.3 vs. 13.7+/-2.1 pA/pF), an increase in the R(i) (214+/-24 vs. 132+/-14 MOmega), but no significant change in I(CaL) or I(KSUS). The I(TO) blocker 4-aminopyridine largely mimicked the changes in phase 1 and ERP associated with chronic beta-blockade, in cells from non-beta-blocked patients. Chronic treatment of patients with calcium channel blockers or angiotensin converting enzyme inhibitors (n=11-13 patients) was not associated with any significant changes in atrial cell electrophysiology.
The observed atrial cellular electrophysiological changes associated with chronic beta-blockade are consistent with a long-term adaptive response, a type of 'pharmacological remodelling', and provide mechanistic evidence supportive of the anti-arrhythmic actions of beta-blockade.
慢性β-肾上腺素能受体拮抗剂(β受体阻滞剂)治疗可降低患者房颤复发率,可能是通过适应性心肌反应实现。然而,其潜在的电生理机制目前尚不清楚。我们旨在研究与β受体阻滞剂及其他心血管活性药物长期治疗相关的人心房细胞电生理变化。
从40例窦性心律且同意参与研究的患者右心耳中酶法分离出心肌细胞。使用全细胞膜片钳记录细胞动作电位时程(APD)、有效不应期(ERP)、L型钙电流(I(CaL))、瞬时外向钾电流(I(TO))和持续外向钾电流(I(KSUS))以及输入电阻(R(i))。采用简单和多元回归分析将药物治疗及临床特征与电生理测量结果进行比较。P<0.05被视为具有统计学意义。
长期接受β受体阻滞剂治疗患者的心房细胞,APD(90)和ERP(刺激频率75次/分钟)显著延长,分别为213±11和233±11毫秒(n = 15例患者),而非β受体阻滞剂治疗患者的细胞分别为176±12和184±12毫秒(n = 11例)。这些细胞的动作电位1期速度也显著降低(22±3对34±3伏/秒)。慢性β受体阻滞剂治疗还与心率显著降低(58±3对69±5次/分钟)、I(TO)密度显著降低(8.7±1.3对13.7±2.1皮安/皮法)、R(i)增加(214±24对132±14兆欧)相关,但I(CaL)或I(KSUS)无显著变化。I(TO)阻滞剂4-氨基吡啶在很大程度上模拟了非β受体阻滞剂治疗患者细胞中与慢性β受体阻滞剂治疗相关的1期和ERP变化。钙通道阻滞剂或血管紧张素转换酶抑制剂长期治疗患者(n = 11 - 13例患者)与心房细胞电生理无任何显著变化相关。
观察到的与慢性β受体阻滞剂治疗相关的心房细胞电生理变化与长期适应性反应一致,即一种“药理学重塑”,并为β受体阻滞剂的抗心律失常作用提供了机制证据支持。